Stocktoria
IRONWOOD PHARMACEUTICALS INC IRWD
IRONWOOD PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M | $346.6M | $298.3M | $274.0M |
| R&D expense | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M | $88.1M | $115.0M | $101.1M | $88.1M | $139.5M |
| SG&A expense | $82.3M | $144.3M | $158.3M | $116.0M | $111.1M | $140.0M | $172.4M | $219.7M | $231.2M | $173.3M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M | $142.9M | $120.1M | -$150.7M | -$15.4M | -$51.9M |
| Interest expense | — | — | $21.6M | $7.6M | $31.1M | $29.5M | $36.6M | $37.7M | $36.4M | $39.2M |
| Income tax | $46.0M | $64.3M | $83.5M | $77.4M | -$327.8M | $2.7M | $0 | $0 | $0 | $0 |
| Net income | $24.0M | $880,000 | -$1.0B | $175.1M | $528.4M | $106.2M | $21.5M | -$282.4M | -$116.9M | -$81.7M |
| EPS (diluted) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | — | — |
| Operating cash flow | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M | $168.8M | $10.7M | -$82.7M | -$108.0M | -$25.9M |
| Free cash flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M | $167.0M | $3.5M | -$83.0M | -$110.8M | -$30.1M |
| Cash & equivalents | $215.5M | $88.6M | $92.2M | $656.2M | $620.1M | $362.6M | $177.0M | $173.2M | $125.7M | $54.0M |
| Inventory | — | — | — | — | — | — | $648,000 | — | $735,000 | $1.1M |
| Total assets | $396.9M | $350.9M | $471.1M | $1.1B | $1.1B | $559.2M | $402.7M | $332.1M | $605.7M | $709.8M |
| Total liabilities | $658.7M | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | -$261.8M | -$301.3M | -$346.3M | $652.4M | $605.9M | $62.6M | -$93.3M | -$196.4M | $9.8M | $66.7M |
Growth · year-over-year · Revenue CAGR 0.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -15.7% | -20.6% | +7.8% | -0.8% | +6.2% | -9.1% | +23.6% | +16.2% | +8.9% | +83.2% |
| Net income growth | +2629.2% | — | -672.5% | -66.9% | +397.7% | +393.7% | — | — | — | — |
| EPS growth | +1400.0% | — | -771.9% | -70.1% | +386.4% | +371.4% | — | — | — | — |
| Free cash flow growth | +22.8% | -43.5% | -33.1% | +4.6% | +56.7% | +4622.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.